Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection ; volume:101 ; number:12 ; day:22 ; month:10 ; year:2022 ; pages:2711-2717 ; date:12.2022
Annals of hematology ; 101, Heft 12 (22.10.2022), 2711-2717, 12.2022
- Urheber
-
Diamantopoulos, Panagiotis T.
Kontandreopoulou, Christina-Nefeli
Stafylidis, Christos
Vlachopoulou, Dimitra
Giannakopoulou, Nefeli
Vardaka, Maria
Mpouhla, Anthi
Variami, Eleni
Galanopoulos, Athanasios
Pappa, Vassiliki
Psichogiou, Mina
Hatzakis, Angelos
Viniou, Nora-Athina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-022-05003-6
- URN
-
urn:nbn:de:101:1-2023012321331157658598
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Diamantopoulos, Panagiotis T.
- Kontandreopoulou, Christina-Nefeli
- Stafylidis, Christos
- Vlachopoulou, Dimitra
- Giannakopoulou, Nefeli
- Vardaka, Maria
- Mpouhla, Anthi
- Variami, Eleni
- Galanopoulos, Athanasios
- Pappa, Vassiliki
- Psichogiou, Mina
- Hatzakis, Angelos
- Viniou, Nora-Athina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Immunogenicity of infectious pathogens and vaccine antigens
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Immunogenicity of infectious pathogens and vaccine antigens
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response
Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Immunogenicity of infectious pathogens and vaccine antigens
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study